CMC support for ncats TDB projects (16-087)
Ended Awarded Last action
- Contract number
- HHSN26100035
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,459,207
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $9,459,207.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost No Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | -$396,735 | |
| Supplemental Agreement for work within scope | $752,393 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $66,959 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $9,036,590 |
Show all 11
About this award
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract supports the Center for Molecular Characterization (CMC) in providing support for projects related to the National Center for Advancing Translational Sciences (NCATS) Therapeutics for Rare and Neglected Diseases (TRND) program. The contract has a ceiling value of $9,459,207.00 and a period of performance through September 30, 2021. This is a delivery order contract with a cost-no-fee pricing type. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a range of biomedical research and facilities support services to federal agencies, particularly the National Institutes of Health (NIH).
Quick answers
Who was awarded contract HHSN26100035?
HHSN26100035 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2016.
How much is contract HHSN26100035 worth?
The government has obligated $9,459,207 on HHSN26100035.
Is contract HHSN26100035 an order under another contract?
Yes. HHSN26100035 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100035 competed?
The extent of competition for HHSN26100035 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award